NCCN 10th Annual Congress: Hematologic Malignancies™

October 16 – 17, 2015
San Francisco Marriott Marquis
Golden Gate Ballroom C - B2 Level
780 Mission Street
San Francisco, California

Friday, October 16, 2015
4:30 – 6:00 PM  •  Exhibits and Refreshments

Saturday, October 17, 2015
7:00 AM – 3:35 PM  •  Exhibits

Print Session Presentations at Your Convenience
The self-serve printing stations are located in the pre-function area.
Sponsored by:
Celgene Corporation; Teva Oncology; ARIAD Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc., An Amgen Subsidiary; and Spectrum Pharmaceuticals, Inc.
Gold Level Sponsor
Celgene Corporation

Silver Level Sponsor
Teva Oncology

Bronze Level Sponsors
ARIAD Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc., An Amgen Subsidiary
Spectrum Pharmaceuticals, Inc.
NCCN recognizes

for their sponsorship of bottled water.

Infinity Pharmaceuticals, Inc. is proud to sponsor the DUETTS program, the global evaluation of the PI3K-δ,γ inhibitor duvelisib in hematologic malignancies. DUETTS is a key part of our mission: to build a community and company capable of sustainably discovering, developing, and delivering innovative, important new medicines to people that make a meaningful difference in their health, well-being, and lives. To learn more, visit INFI.com.

Duvelisib is an investigational compound. Its safety and efficacy have not been evaluated by the US Food and Drug Administration or any other health authority.

© 2015 Infinity Pharmaceuticals, Inc. Cambridge, MA 02139 August 2015. 145-2015-038

UNITE AGAINST B-CELL MALIGNANCIES

FOR IMPACT ON A GREATER SCALE, WE MAY NEED A COMPLEMENTARY APPROACH: DUAL INHIBITION OF PI3K-δ,γ

To learn more about dual inhibition of PI3K-δ,γ, please visit www.duettprogram.com
Committed to delivering additional treatment options
ON SEPTEMBER 5, 1975, Fred Hutchinson Cancer Research Center opened its doors in Seattle. 40 years and 1 million bone marrow transplants around the world later, we keep pushing toward the next inconceivable discovery. GET INSPIRED AT fredhutch.org
Seating is available in the exhibition hall for breakfast, lunch, and breaks.

### Exhibitor Name

<table>
<thead>
<tr>
<th>Exhibitor Name</th>
<th>Exhibit #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actelion Pharmaceuticals US Inc.</td>
<td>12</td>
</tr>
<tr>
<td>Adaptive Biotechnologies</td>
<td>7</td>
</tr>
<tr>
<td>Alexion Pharmaceuticals</td>
<td>23</td>
</tr>
<tr>
<td>Amgen</td>
<td>3</td>
</tr>
<tr>
<td>ARIAD Pharmaceuticals, Inc.</td>
<td>17</td>
</tr>
<tr>
<td>Astellas Pharma US, Inc.</td>
<td>28</td>
</tr>
<tr>
<td>Baxalta</td>
<td>6</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>34</td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td>1</td>
</tr>
<tr>
<td>Genentech USA, Inc.</td>
<td>4</td>
</tr>
<tr>
<td>Genzyme, a Sanofi Company</td>
<td>32</td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td>22</td>
</tr>
<tr>
<td>Harborside Press</td>
<td>25</td>
</tr>
<tr>
<td>Incyte Corporation</td>
<td>9</td>
</tr>
<tr>
<td>Infinity Pharmaceuticals, Inc.</td>
<td>19</td>
</tr>
<tr>
<td>Janssen Pharmaceuticals, Division of Johnson &amp; Johnson</td>
<td>21</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>5</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>31</td>
</tr>
<tr>
<td>NeoGenomics Laboratories</td>
<td>10</td>
</tr>
<tr>
<td>Novartis Oncology</td>
<td>2</td>
</tr>
<tr>
<td>Onyx Pharmaceuticals, Inc., An Amgen Subsidiary</td>
<td>20</td>
</tr>
<tr>
<td>Pfizer</td>
<td>35</td>
</tr>
<tr>
<td>Pharmacyclics LLC, an AbbVie Company</td>
<td>30</td>
</tr>
<tr>
<td>*Roswell Park Cancer Institute</td>
<td>29</td>
</tr>
<tr>
<td>Sandoz</td>
<td>14</td>
</tr>
<tr>
<td>Seattle Genetics</td>
<td>33</td>
</tr>
<tr>
<td>Spectrum Pharmaceuticals, Inc.</td>
<td>16</td>
</tr>
<tr>
<td>*Stanford Health Care</td>
<td>15</td>
</tr>
<tr>
<td>Sunesis Pharmaceuticals, Inc.</td>
<td>24</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>8</td>
</tr>
<tr>
<td>Teva Oncology</td>
<td>18</td>
</tr>
<tr>
<td>The Binding Site</td>
<td>13</td>
</tr>
<tr>
<td>The Leukemia &amp; Lymphoma Society</td>
<td>11</td>
</tr>
</tbody>
</table>

* NCCN Member Institution
Astellas Pharma US, Inc.

Astellas Pharma US, Inc., a subsidiary of Tokyo-based Astellas Pharma, Inc., is a research-based pharmaceutical company dedicated to improving the health of people around the world through innovative pharmaceutical products. Astellas ranks among the top 20 pharmaceutical companies in the world. For more information on Astellas, please go to www.astellas.com/us.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals combines high-throughput sequencing and bioinformatics to profile the adaptive immune repertoire. ARIAD's first clinical application is the clonoSEQ® Process, which empowers physicians with ultra-sensitive MRD detection and quantification for patients with lymphoid cancers. ClonoSEQ results are generated in seven days using the company's CLIA-certified, CAP-accredited laboratory. Physicians are provided with a simple, actionable report showing a patient's MRD status and level, as well as MRD trends over time via a secure online portal.

Actelion Pharmaceuticals US Inc.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Adaptive Biotechnologies

Adaptive Biotechnologies combines high-throughput sequencing and bioinformatics to profile the adaptive immune repertoire. Adaptive's first clinical application is the clonoSEQ® Process, which empowers physicians with ultra-sensitive MRD detection and quantification for patients with lymphoid cancers. ClonoSEQ results are generated in seven days using the company's CLIA-certified, CAP-accredited laboratory. Physicians are provided with a simple, actionable report showing a patient's MRD status and level, as well as MRD trends over time via a secure online portal.

Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation.

The treatment is currently approved in more than 40 countries for the treatment of PNH, and in the United States and the European Union for the treatment of aHUS. Alexion is evaluating other potential indications for its marketed drug and is developing four other highly innovative biotechnology product candidates, which are being investigated across additional severe and ultra-rare disorders.

Baxalta

Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients' lives, Baxalta's broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms. Launched in 2015 following separation from Baxter International, Baxalta's heritage in biopharmaceuticals spans decades.

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Genentech USA, Inc.

Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Learn more at: www.genzyme.com.

Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions.
A partial list of amazing things Greg can do.

Amazing because in 2004, Greg was diagnosed with inoperable lung cancer and given one year to live.

Eleven years later, he’s alive and well thanks to breakthrough targeted cancer therapy from the Mass General Cancer Center. And now, for Greg and others like him, every day is an amazing day.

massgeneral.org/cancer

Everyday Amazing

Kyprolis<sup>™</sup> (carfilzomib) for Injection

Takes Flight

For more information Visit KYPROLIS.com
Harborside Press
Exhibit # 25
Harborside Press is the publisher of JNCCN-Journal of the National Comprehensive Cancer Network, which covers the entire spectrum of cancer care and includes updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); The ASCO Post, a newspaper featuring highly validated coverage of important issues in the field of oncology; and the Journal of the Advanced Practitioner in Oncology, a clinical journal for the nurse practitioner, clinical nurse specialist, and physician assistant.

Infinity Pharmaceuticals, Inc.
Exhibit # 19
Infinity is an innovative biopharmaceutical company dedicated to discovering, developing, and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways.

Janssen Pharmaceuticals, Division of Johnson & Johnson
Exhibit # 21
At Janssen, what matters most is helping people live full and healthy lives. Inspired by the millions of people impacted by cardiovascular and metabolic diseases, we pursue the most promising science, wherever it might be found. We collaborate with the world for the health of everyone in it.

Jazz Pharmaceuticals
Exhibit # 5
Jazz Pharmaceuticals (NASDAQ:JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Merck & Co., Inc.
Exhibit # 31
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs, and partnerships that donate and deliver our products to the people who need them. For more information, visit www.merck.com.

NeoGenomics Laboratories
Exhibit # 10
NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community. NeoGenomics offers the complete spectrum of diagnostic services in immunohistochemistry, FISH, flow cytometry, cytogenetics, and molecular testing through our nationwide network of laboratories. We are dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients.

Novartis Oncology
Exhibit # 2
Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology—understanding how cancer develops on a genomic level and developing drugs that hone in on those targets. For more information, visit www.novartisoncology.com.

Onyx Pharmaceuticals, Inc., An Amgen Subsidiary
Exhibit # 20
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company’s website at www.onyx.com. Onyx Pharmaceuticals is on Twitter. Sign up to follow our Twitter feed @OnyxPharm at www.twitter.com/OnyxPharm.

Pfizer
Exhibit # 35
Pfizer Oncology is committed to the research and discovery of breakthrough treatment options, including small molecules, biologics and immunotherapies, to improve the outlook for cancer patients worldwide. For more information please visit www.pfizer.com.

Pharmacyclics LLC, an AbbVie Company
Exhibit # 30
Pharmacyclics LLC, a wholly-owned subsidiary of AbbVie, is focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune-mediated diseases. Pharmacyclics’ mission is to develop and commercialize novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical needs.

Pharmacyclics markets IMBRUVICA and has two product candidates in clinical development and several preclinical molecules in lead optimization. Pharmacyclics is committed to high standards of ethics, scientific rigor and operational efficiency as it moves each of these programs toward commercialization. To learn more, please visit www.pharmacyclics.com.
Ranked among the top cancer hospitals in the nation in U.S. News & World Report’s 2015-16 Best Hospitals.

Imagine what you could do at a world-renowned cancer center like Roswell Park Cancer Institute.

Imagine... working among 3,000 scientific, academic, and medical minds joined together in one mission:

to understand, prevent and cure cancer.

The Department of Medicine at Roswell Park is recruiting for the following positions:

- Chief of Melanoma/Sarcoma
- Medical oncologists with clinical and research interests in:
  - lymphoma | myeloma | gastrointestinal oncology
- Hospitalist

Direct inquiries can be made to Kathryn Hall at 716-845-4137 or Kathryn.Hall@RoswellPark.org.

Visit the Roswell Park booth, exhibit #29, for more information about these opportunities and the career that’s waiting for you at Roswell Park.

We’re Recruiting...
Roswell Park Cancer Institute (RPCI)
Exhibit # 29
Since 1898, Roswell Park Cancer Institute (RPCI) in Buffalo, NY, has forged an exemplary reputation with the combined strength of its basic/translational research, multidisciplinary oncology teams, educational programs and compassionate staff. A seamless interface of scientific inquiry and clinical application, and an aggressive clinical trials program, afford patients access to breakthroughs in cancer diagnostics, technology and therapies. A charter member of the NCCN, RPCI is the only NCI-designated comprehensive cancer center in Upstate New York.

Sandoz
Exhibit # 14
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz’s portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefited from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).

Seattle Genetics
Exhibit # 33
Seattle Genetics is a biotechnology company focused on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer. Seattle Genetics has collaborations and co-development agreements for its antibody-drug conjugate (ADC) technology with a number of leading biotechnology and pharmaceutical companies. Find more information at www.seattlegenetics.com.

Spectrum Pharmaceuticals, Inc.
Exhibit # 16
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a focus in oncology and hematology. Spectrum currently markets five oncology/hematology drugs. Spectrum has a growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. For more information visit: www.sppirx.com.

Stanford Health Care
Exhibit # 15
The Stanford Cancer Institute (SCI) is committed to giving patients every clinical and technological advantage in the prevention and treatment of cancer. The SCI leverages the expertise of over 300 physicians and researchers working together to unravel cancer’s secrets. Stanford’s scientific focus includes cancer cell and stem cell biology, immunology, molecular imaging and genetics. Translational medicine is the cornerstone of Stanford’s cancer treatment programs, combining new advances with compassionate care and supportive services.

Sunesis Pharmaceuticals, Inc.
Exhibit # 24
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers.

Takeda Oncology
Exhibit # 8
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

Teva Oncology
Exhibit # 18
People are at the heart of what drives Teva Oncology. As a top 10 oncology company in the US, we strive to improve the lives of people affected by cancer. Our pipeline of small molecules and biologics target solutions in hematologic malignancies, solid tumors and supportive care. At Teva Oncology, our vision is to change the course of cancer care one patient at a time.

The Binding Site
Exhibit # 13
Binding Site is committed to developing special protein assays and automated systems for the improvement of patient care. Our market-leading, guideline-recommended free light chain test, Freelite® is widely used in diagnosis and monitoring of myeloma. Hevylite®, our newest test for monitoring of myeloma patient care was recently launched in the USA, and we have partnered with eBioscience for clinical flow cytometry reagents. Visit us at www.thebindingsite.com

The Leukemia & Lymphoma Society
Exhibit # 11
LLS exists to find cures and ensure access to treatments for blood cancer patients. We are the voice for all blood cancer patients and we work to ensure access to treatments for all blood cancer patients.
At the University of Michigan Comprehensive Cancer Center, patients with hematologic malignancies receive the most advanced, evidenced-based care, with access to targeted and personalized new therapies. At any given time, we have dozens of open clinical trials, for patients with blood cancer, with many of them based on the large number of experimental drugs we are developing at the Cancer Center.

Find out more at mcancer.org.
This is no routine cancer hospital.

At The James at The Ohio State University, the third-largest cancer hospital in the nation, we understand that each person’s cancer is unique. Here, the world’s brightest researchers, oncologists and other specialists work together, focused solely on discovering, developing and delivering the most effective treatment for all types of cancer. To successfully detect and treat each cancer, sub-specialized cancer physicians must work side-by-side with cancer researchers, to understand the disease at the molecular level and determine which treatments will stop it. The James brings together the latest, cutting-edge technology and these teams of experts in an amazing structure designed for one purpose...our patients. To learn more, visit cancer.osu.edu/noroutinehospital.

The James
LEADING THE WAY CANCER IS TREATED TODAY AND TOMORROW

The Stanford Cancer Institute (SCI) is committed to giving patients every clinical and technological advantage in the prevention and treatment of cancer. The SCI leverages the expertise of over 300 physicians and researchers working together to unravel cancer's secrets. Stanford’s scientific focus includes cancer cell and stem cell biology, immunology, molecular imaging and genetics. Translational medicine is the cornerstone of Stanford’s cancer treatment programs, combining new advances with compassionate care and supportive services.

Stanford Cancer Institute

AN NCI-DESIGNATED COMPREHENSIVE CANCER CENTER

Advancing the Science and Medicine of Cancer Care

Through integrating exceptional care, innovative research and outstanding educational programs, we are redefining what is possible for cancer patients and their families.

www.ucsfhealth.org/cancer
Joan is more than just a patient going through chemotherapy. We see so much more than just cancer. Joan is already busy enough with hockey practices, dance recitals, and science fair supply shopping. Now she’s making room on the kitchen calendar for Q3W therapy sessions.

People like Joan are at the heart of what drives Teva Oncology. With over 100 years of global pharmaceutical expertise, our mission is to provide solutions that advance cancer care and improve the lives of people affected by cancer.

We treat the person, not just the cancer.